Syndax Pharmaceuticals (SNDX) Income Statement: Revenue & Earnings

Syndax Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Syndax Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	23.68	0.00	0.00	139.71	1.52
Cost of Revenue	0.83	163.03	118.50	0.00	0.00
Gross Profit	22.85	-163.03	-118.50	139.71	1.52
Operating Expenses
Research & Development	241.65	163.03	118.50	88.25	50.44
Selling, General & Administrative	120.88	66.92	33.26	25.24	22.51
Operating Expenses	362.53	229.95	151.76	113.49	72.94
Operating Income	-339.67	-229.95	-151.76	26.22	-71.42
Other Income/Expense
Interest Income	26.09	21.16	5.87	0.40	0.84
Interest Expense	4.93	0.21	3.14	-1.90	-2.36
Other Income/Expense	-0.25	-0.36	-0.32	0.20	-0.22
Income
Income Before Tax	-318.76	-209.36	-149.34	24.93	-73.16
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-318.76	-209.36	-149.34	24.93	-73.16
Net Income - Continuous Operations	-318.76	-209.36	-149.34	24.93	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-313.82	-209.14	-146.17	26.26	-71.33
EBIT	-313.83	-209.15	-146.20	26.22	-71.42
Depreciation & Amortization	0.01	0.01	0.03	0.04	0.09
Earnings Per Share
Basic EPS	-4.00	-3.00	-2.00	-	-2.00
Diluted EPS	-4.00	-3.00	-2.00	-	-2.00
Basic Shares Outstanding	85.62	70.37	60.76	52.06	41.31
Diluted Shares Outstanding	85.62	70.37	60.76	53.62	41.31